ImpriMed will be attending ASCO to engage with oncology leaders and explore advancements in precision medicine. We look forward to connecting with collaborators interested in ex vivo drug sensitivity testing and AI-driven approaches to personalized cancer treatment.
Click here to go to the official event page →ImpriMed will be attending ASCO to engage with oncology leaders and explore advancements in precision medicine. We look forward to connecting with collaborators interested in ex vivo drug sensitivity testing and AI-driven approaches to personalized cancer treatment.
